Edition:
India

Aclaris Therapeutics Receives FDA Approval For Eskata For Treatment Of Raised SKs


Friday, 15 Dec 2017 

Dec 15 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS - FDA APPROVAL OF ESKATA BASED ON 2 PIVOTAL PHASE 3 TRIALS THAT SHOWED SAFETY & EFFICACY OF ESKATA FOR TREATMENT OF RAISED SKS. 

Company Quote

2.1
 --
18 Jul 2019